Small orphan drug firms caught by Germany's AMNOG assessments
This article was originally published in Scrip
Small companies with orphan drug products whose turnover is less than €50 million are not excluded from cost-effectiveness assessments introduced this year under Germany’s healthcare reform act, said Dr Alexander Natz, Brussels representative for the BPI, the German association for mid-sized pharma companies. In an interview with Scrip, he warned companies not to be complacent
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.